A Boston-area biotechnology firm announced it has received a patent titled “Carboxylated Psilocybin Derivatives and Methods of Using” for its EVM301 series of molecules to treat a range of mental health disorders.
A Boston-area biotechnology firm announced it has received a patent titled “Carboxylated Psilocybin Derivatives and Methods of Using” for its EVM301 series of molecules to treat a range of mental health disorders.
Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.
